Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Recovery 8% Improvement Relative Risk Viral clearance -58% c19early.org/d Abroug et al. NCT04883203 Vitamin D RCT LONG COVID Favors vitamin D Favors control
Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 patients: A randomized-controlled clinical trial
Abroug et al., Research Square, doi:10.21203/rs.3.rs-1276203/v1 (Preprint), NCT04883203 (history)
21 Jul 2022    Source   PDF   Share   Tweet
Long COVID RCT with mostly asymptomatic patients that remained PCR positive for 14 days, showing slower viral conversion with treatment. Authors report "a 30-day follow-up of our patients showed that a long-lasting COVID-19 was noted in 34.5% of patients who received vitamin D and in 38.9% of patients who belonged to the placebo group", however no number of the reported group sizes matches these percentages. Authors do not define "long-lasting COVID-19" which does not match the viral clearance at 30 days shown in Figure 2, and is also unexpected in terms of symptoms according to the baseline symptomatic status. Details and timing of PCR tests are not provided. According to Figure 3, testing appears to have been sporadic - for example ~23 treatment patients remain PCR+ at day 40, however no more than one unique Ct value per day is shown.
risk of no recovery, 8.5% lower, RR 0.92, p = 0.85, treatment 20 of 57 (35.1%), control 23 of 60 (38.3%), NNT 31, approximate, reported percentages do not match group sizes, day 30.
risk of no viral clearance, 58.0% higher, HR 1.58, p = 0.01, treatment 57, control 60, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abroug et al., 21 Jul 2022, Randomized Controlled Trial, placebo-controlled, Tunisia, preprint, mean age 42.7, 16 authors, study period May 2020 - August 2020, dosage 200,000IU single dose, trial NCT04883203 (history).
Contact: hela-abr@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit